Current directions in the treatment of early stage Hodgkin’s lymphoma

Published: June 8, 2009
Abstract Views: 164
PDF: 367
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Radiation therapy (RT) alone and the combined modalities therapies (CMT) of chemotherapy and RT for early stage Hodgkin lymphoma have achieved excellent results for early stage Hodgkin lymphoma for over thirty years. A major concern has been the late toxicities of treatment most of which are attributable to the RT. Recently several studies have suggested that chemotherapy alone is a reasonable treatment option for patients with early stage non-bulky Hodgkin lymphoma. At the present time this does not seem to be appropriate for patients with early stage bulky disease (mediastinal mass > 1/3rd the thoracic diameter or peripheral nodal mass > 10 cm, since RT to regions of tumor bulk in combination with chemotherapy has been demonstrated to reduce the risk of recurrence.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Straus, D. (2009). Current directions in the treatment of early stage Hodgkin’s lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.401